Mwanzo084990 • KOSDAQ
add
Helixmith Co Ltd
Bei iliyotangulia
₩ 2,845.00
Bei za siku
₩ 2,795.00 - ₩ 2,870.00
Bei za mwaka
₩ 2,500.00 - ₩ 7,440.00
Thamani ya kampuni katika soko
129.75B KRW
Wastani wa hisa zilizouzwa
elfu 73.24
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
KOSDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.80B | 65.09% |
Matumizi ya uendeshaji wa biashara | 5.81B | -30.08% |
Mapato halisi | -3.79B | 54.16% |
Kiwango cha faida halisi | -210.47 | 72.24% |
Mapato kwa kila hisa | — | — |
EBITDA | -3.97B | 24.02% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 70.45B | -16.48% |
Jumla ya mali | 149.90B | -34.10% |
Jumla ya dhima | 6.08B | -79.04% |
Jumla ya hisa | 143.83B | — |
hisa zilizosalia | 46.05M | — |
Uwiano wa bei na thamani | 0.91 | — |
Faida inayotokana na mali | -8.32% | — |
Faida inayotokana mtaji | -8.66% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (KRW) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -3.79B | 54.16% |
Pesa kutokana na shughuli | -4.52B | 7.87% |
Pesa kutokana na uwekezaji | 32.00B | 121.76% |
Pesa kutokana na ufadhili | -6.68M | 99.86% |
Mabadiliko halisi ya pesa taslimu | 27.80B | 474.69% |
Mtiririko huru wa pesa | 523.28M | 107.32% |
Kuhusu
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Ilianzishwa
Nov 1996
Tovuti
Wafanyakazi
72
